Amgen Inc. (AMGN) FY2025 Q3 P&L / Income Statement
2025-07-01 to 2025-09-30
Revenue by Product and Service by Geography
2025-07-01 to 2025-09-30
Swipe to see the full flow
Chart details
Amgen Inc. (AMGN) FY2025 Q3 P&L / Income Statement
Income statement for 2025-07-01 through 2025-09-30. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.
- Total revenues
- 9,557,000,000 US dollars
- Cost of sales
- 3,082,000,000 US dollars
- Gross profit (calculated)
- 6,475,000,000 US dollars
- Operating expenses (calculated)
- 3,949,000,000 US dollars
- Operating income
- 2,526,000,000 US dollars
- Other income (expense), net (calculated)
- 1,395,000,000 US dollars
- Income before income taxes
- 3,921,000,000 US dollars
- Provision for income taxes
- 705,000,000 US dollars
- Net income
- 3,216,000,000 US dollars
- Aranesp - UNITED STATES
- 103,000,000 US dollars
- Aranesp - Non-US
- 254,000,000 US dollars
- BLINCYTO - UNITED STATES
- 236,000,000 US dollars
- BLINCYTO - Non-US
- 156,000,000 US dollars
- EVENITY - UNITED STATES
- 417,000,000 US dollars
- EVENITY - Non-US
- 124,000,000 US dollars
- ENBREL - UNITED STATES
- 574,000,000 US dollars
- ENBREL - Non-US
- 6,000,000 US dollars
- KRYSTEXXA - UNITED STATES
- 320,000,000 US dollars
- KRYSTEXXA - Non-US
- 0 US dollars
- Kyprolis - UNITED STATES
- 225,000,000 US dollars
- Kyprolis - Non-US
- 134,000,000 US dollars
- Nplate - UNITED STATES
- 333,000,000 US dollars
- Nplate - Non-US
- 124,000,000 US dollars
- Otezla - UNITED STATES
- 473,000,000 US dollars
- Otezla - Non-US
- 112,000,000 US dollars
- Other products - UNITED STATES
- 1,408,000,000 US dollars
- Other products - Non-US
- 445,000,000 US dollars
- Prolia - UNITED STATES
- 806,000,000 US dollars
- Prolia - Non-US
- 333,000,000 US dollars
- Repatha - UNITED STATES
- 442,000,000 US dollars
- Repatha - Non-US
- 352,000,000 US dollars
- TEPEZZA - UNITED STATES
- 518,000,000 US dollars
- TEPEZZA - Non-US
- 42,000,000 US dollars
- TEZSPIRE - UNITED STATES
- 377,000,000 US dollars
- TEZSPIRE - Non-US
- 0 US dollars
- Vectibix - UNITED STATES
- 162,000,000 US dollars
- Vectibix - Non-US
- 122,000,000 US dollars
- XGEVA - UNITED STATES
- 357,000,000 US dollars
- XGEVA - Non-US
- 182,000,000 US dollars
- Product sales - UNITED STATES
- 6,751,000,000 US dollars
- Product sales - Non-US
- 2,386,000,000 US dollars
- Selling, general and administrative
- 1,720,000,000 US dollars
- Research and development
- 1,900,000,000 US dollars
- Other
- 329,000,000 US dollars
- Revenue before reconciliation (calculated)
- 18,274,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.
- Components above reported revenue (calculated)
- negative 8,717,000,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item.
Chart connections
- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG
Gross margin
67.8%
Gross profit / revenue
Operating margin
26.4%
Operating profit / revenue
Cash conversion
145.6%
Operating cash / net income, same period
Product waitlist
Health Check and Teardown for your own company
A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!